Go Premium in Our Biggest Sale Ever

Go Ultimate 75% OFF

TSE:MSCL Stock Latest News

Company AnnouncementsSatellos Bioscience Files September 30, 2026 Interim Financial Statements1d ago6K MSLE

The FlySatellos reports Q3 EPS (53c), consensus (63c)1d agoMSLE
Company AnnouncementsSatellos Changes Primary Endpoint in Pediatric Duchenne Trial After FDA Feedback1w ago6K MSLE
The FlySatellos changes primary endpoint in BASECAMP trial after FDA feedback1w agoMSLE
Company AnnouncementsSatellos to Update Investors on BASECAMP DMD Study Strategy1w ago6K MSLE

Satellos Bioscience Forms Scientific Advisory Board to Expand Regeneration and Neuroscience Research

Company AnnouncementsSatellos Bioscience Forms Scientific Advisory Board to Expand Regeneration and Neuroscience Research2w ago6K MSLE

Company AnnouncementsSatellos Bioscience to Court Investors at November Healthcare Conferences3w ago6K MSLE

The FlySatellos management to meet with Cantor1M agoMSLE

The FlyCraig-Hallum initiates Satellos with a Buy ahead of BASECAMP data1M agoMSLE
The FlySatellos initiated with a Buy at Craig-Hallum1M agoMSLE
Company AnnouncementsSatellos Secures Long-Term U.S. Patent Protection for Lead Drug Forazapadin1M ago6K MSLE
The FlySatellos granted composition of matter patent for forazapadin1M agoMSLE

Analyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress

RatingsAnalyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress1M agoMSLE

Company AnnouncementsSatellos Completes Enrollment in BASECAMP Phase 2 Trial of Forazapadin for Duchenne Muscular Dystrophy1M ago6K MSLE

The FlySatellos announces enrollment completed for BASECAMP1M agoMSLE

RatingsSatellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $221M agoMSLE
Company AnnouncementsSatellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding1M agoMSLE
The FlySatellos announces U.S. FDA cleared IND application for forazapadin1M agoMSLE
Company AnnouncementsSatellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress1M ago6K MSLE

Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance

Company AnnouncementsSatellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance2M ago6K MSLE

The FlySatellos assigns forazapadin name to SAT-32472M agoMSLE

Company AnnouncementsSatellos Bioscience to Showcase DMD Drug Program at September Investor Conferences2M ago6K MSLE